133 related articles for article (PubMed ID: 16027522)
1. Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
Yeh KH; Yeh SH; Wan JP; Shen YC; Cheng AL
Anticancer Drugs; 2005 Aug; 16(7):739-42. PubMed ID: 16027522
[TBL] [Abstract][Full Text] [Related]
2. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Masuda T; Imai H; Kuwako T; Miura Y; Yoshino R; Kaira K; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Clin Transl Oncol; 2015 Sep; 17(9):702-9. PubMed ID: 25990507
[TBL] [Abstract][Full Text] [Related]
4. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
Han JY; Park K; Kim SW; Lee DH; Kim HY; Kim HT; Ahn MJ; Yun T; Ahn JS; Suh C; Lee JS; Yoon SJ; Han JH; Lee JW; Jo SJ; Lee JS
J Clin Oncol; 2012 Apr; 30(10):1122-8. PubMed ID: 22370314
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
D'Addario G; Rauch D; Stupp R; Pless M; Stahel R; Mach N; Jost L; Widmer L; Tapia C; Bihl M; Mayer M; Ribi K; Lerch S; Bubendorf L; Betticher DC
Ann Oncol; 2008 Apr; 19(4):739-45. PubMed ID: 18096565
[TBL] [Abstract][Full Text] [Related]
6. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
Yuan Y; Tan C; Li M; Shen H; Fang X; Hu Y; Ma S
World J Surg Oncol; 2012 Nov; 10():235. PubMed ID: 23134665
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
Lee KH; Han SW; Hwang PG; Oh DY; Kim DW; Chung DH; Im SA; Kim TY; Heo DS; Bang YJ
Jpn J Clin Oncol; 2006 Jun; 36(6):344-50. PubMed ID: 16818479
[TBL] [Abstract][Full Text] [Related]
8. Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
Lu RL; Hu CP; Yang HP; Li YY; Gu QH; Wu L
Pathol Oncol Res; 2014 Apr; 20(2):445-51. PubMed ID: 24297623
[TBL] [Abstract][Full Text] [Related]
9. Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.
Lee Y; Han JY; Kim HT; Yun T; Lee GK; Kim HY; Lee JS
J Neurooncol; 2013 Oct; 115(1):95-101. PubMed ID: 23832498
[TBL] [Abstract][Full Text] [Related]
10. Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
Kozlov V; Karpov I; Kovalenko S; Shamanin V
Exp Oncol; 2017 Jul; 39(2):155-156. PubMed ID: 29483495
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.
Iuchi T; Shingyoji M; Sakaida T; Hatano K; Nagano O; Itakura M; Kageyama H; Yokoi S; Hasegawa Y; Kawasaki K; Iizasa T
Lung Cancer; 2013 Nov; 82(2):282-7. PubMed ID: 24021541
[TBL] [Abstract][Full Text] [Related]
12. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.
Tokumo M; Toyooka S; Kiura K; Shigematsu H; Tomii K; Aoe M; Ichimura K; Tsuda T; Yano M; Tsukuda K; Tabata M; Ueoka H; Tanimoto M; Date H; Gazdar AF; Shimizu N
Clin Cancer Res; 2005 Feb; 11(3):1167-73. PubMed ID: 15709185
[TBL] [Abstract][Full Text] [Related]
13. Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature.
Marech I; Vacca A; Gnoni A; Silvestris N; Lorusso V
Tumori; 2013; 99(5):e241-4. PubMed ID: 24362878
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
Han SW; Kim TY; Lee KH; Hwang PG; Jeon YK; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ
Lung Cancer; 2006 Nov; 54(2):201-7. PubMed ID: 16956694
[TBL] [Abstract][Full Text] [Related]
15. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
[TBL] [Abstract][Full Text] [Related]
16. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
Taron M; Ichinose Y; Rosell R; Mok T; Massuti B; Zamora L; Mate JL; Manegold C; Ono M; Queralt C; Jahan T; Sanchez JJ; Sanchez-Ronco M; Hsue V; Jablons D; Sanchez JM; Moran T
Clin Cancer Res; 2005 Aug; 11(16):5878-85. PubMed ID: 16115929
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of lung cancer with gefitinib and EGFR mutation status determination using EBUS-TBNA samples in an extremely old patient.
Nishimura H; Nakajima T; Itakura M; Shingyoji M; Iizasa T; Kimura H
Intern Med; 2009; 48(21):1905-7. PubMed ID: 19881244
[TBL] [Abstract][Full Text] [Related]
18. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
19. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Yang JC; Wu YL; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu CP; O'Byrne K; Feng J; Lu S; Huang Y; Geater SL; Lee KY; Tsai CM; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su WC; Lee KH; Kato T; Massey D; Shahidi M; Zazulina V; Sequist LV
Lancet Oncol; 2015 Feb; 16(2):141-51. PubMed ID: 25589191
[TBL] [Abstract][Full Text] [Related]
20. A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.
Xing K; Zhou X; Zhao X; Sun S; Luo Z; Wang H; Yu H; Wang J; Chang J; Wu X; Hu A
Med Oncol; 2014 Jul; 31(7):36. PubMed ID: 24908064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]